drugset / Trial / NCT03235050
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382
Timeline
- Start
- 2017-08-02
- Primary completion
- 2018-05-03
- Completion
- 2019-06-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cotadutide | Peptide | 100 ug | Subcutaneous |
| Subject | Cotadutide | Peptide | 200 ug | Subcutaneous |
| Subject | Cotadutide | Peptide | 300 ug | Subcutaneous |
| Comparator | Liraglutide | Peptide | 1.8 mg | Subcutaneous |